Cyclana Bio: redefining women’s health
Longevity Technology - 30-Oct-2025Using menstrual fluid, Cyclana builds tissue models to tackle endometriosis and chronic inflammation
Join the club for FREE to access the whole archive and other member benefits.
Contributing editor to Longevity Technology
Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
Details last updated 10-Feb-2020
Using menstrual fluid, Cyclana builds tissue models to tackle endometriosis and chronic inflammation
Cambridge biotech to trial USP30 inhibitor MTX325 to boost mitochondrial repair in Parkinson’s
Biotech startup Elevara aims to transform RA treatment with a non-immunosuppressive oral drug
NewLimit’s $45M raise advances youthful liver and immune cell restoration in preclinical studies
PP405 shows early promise in reactivating dormant hair follicles to restore growth
Trials showed fewer hospital visits and faster access to care
Partnership aims to uncover disease-driving genes and boost precision drug development
Cirrus Therapeutics targets aging biology to combat blindness from dry AMD
Startup scaled cryopreservation from neural slices to large-animal organs, eyeing human trials
First BioAgent generated 1,000+ hypotheses, raised $900K, and drove lab testing within weeks
New multi-agent AI analyzes massive datasets to predict biological age in weeks, not years
Using donated organs, Revalia aims to cut drug failures and speed safe treatments to patients
Funding backs trials of NRG5051, aiming to slow ALS and Parkinson’s by protecting neurons
Experimental RNAi drug aims to silence alpha-synuclein and slow neurodegeneration
$350K grant fuels Minovia’s biomarker work, as early trials show promising patient gains
Startup uses AI to explore billions of molecules for next-gen skincare innovation
New funding will help expand OneSkin’s reach and target ageing at the cellular level
With $19 million funding, the startup plans regulatory approvals and scaling
The fund bridges East-West collaboration and acts quickly using its own capital
New investment fuels development of therapies targeting mtDNA-related energy disorders